Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Scilex Holding CompanyNASDAQ: SCLX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $3.21M rose 30.7% year over year, behind the +138.8% change in trailing-twelve-month research & development. Sequentially, it fell 60.7% from the prior quarter. Over 3 fiscal years it compounded at +31.8% a year.

Context

  • Research & development amounted to 68.5% of revenue in FY2025, up 51.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +30.7% toward the trailing-twelve-month pace of +138.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.21M-60.7% QoQ
Last fiscal yearDec 2025
$20.71M+114.8% YoY
LTMMar 2026
$21.46M+138.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.7%——
1 year+114.8%——
3-year CAGR+31.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
20.71M USD
Year-over-year change
+114.8%
4-year CAGR
+22.5%

Research & Development vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 research & development of $21.46M is the 7th highest of the 9 companies compared; the peer median is $39.93M.
  • Its year-over-year change of +138.8% is the highest of 9, against a peer median of -19.2%.
  • Research & development amounts to 63.4% of revenue for SCLX, versus a peer median of 190.6%.
SCLX Competitors Peer median
Research & Development for SCLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M -37.7%-16.4%622.7%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M -9.9%+48.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M -27.2%-33.9%—
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
SCLXScilex Holding CompanyLTM Mar 2026$21.46M +138.8%+31.8%63.4%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
CTORCitius Oncology, Inc.LTM Mar 2026$4.11M -39.8%-2.2%73.3%
Peer median (excluding SCLX) $39.93M-19.2%-2.2%190.6%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.32M38.03M46.74M56.59M30.25M
Cost of Revenue3.63M10.8M15.68M16.69M15.22M
Gross Profit27.68M27.24M31.06M39.9M15.03M
Gross Margin88.4%71.6%66.5%70.5%49.7%
Research & Development9.2M9.05M12.75M9.64M20.71M
Selling, General & Admin50.58M64.9M119.64M119.02M266.63M
Operating Expenses63.52M77.87M136.49M123.3M287.34M
Depreciation & Amortization3.78M4.45M4.15M4.05M4.62M
EBITDA(72.88M)(9.3M)(109.1M)(66.8M)(357.95M)
EBITDA Margin-232.7%-24.5%-233.4%-118.0%-1183.2%
Operating Income(35.84M)(50.63M)(105.43M)(83.4M)(272.3M)
Operating Margin-114.4%-133.1%-225.6%-147.4%-900.1%
Interest Income00000
Interest Expense11.76M9.6M1.07M1.96M11.46M
Other Income / Expenses(52.58M)27.27M(8.89M)10.59M(101.72M)
Income Before Tax(88.42M)(23.36M)(114.32M)(72.81M)(374.03M)
Pre-Tax Margin-282.3%-61.4%-244.6%-128.7%-1236.3%
Income Tax Expense5K4K13K(1K)26K
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Net Margin-282.4%-61.4%-244.6%-128.7%-1185.8%
EPS (Basic)(23.29)(6.09)(44.85)(19.43)(36.48)
EPS (Diluted)(23.29)(6.09)(44.85)(19.43)(36.48)
Weighted Avg Shares3.8M3.83M3.72M6.95M11.03M
Weighted Avg Shares (Diluted)3.8M3.83M3.72M6.95M11.03M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.